違禁品膠體金單克隆抗原

廣州健侖生物科技有限公司

廣州健侖生物科技有限公司是集研制開發(fā)、銷售、服務(wù)于一體的優(yōu)良企業(yè),公司產(chǎn)品涉及臨床快速診斷試劑、食品安全檢測試劑，違禁品快速檢測，動(dòng)物疾病防疫檢測試劑，免疫診斷試劑、臨床血液學(xué)和體液學(xué)檢驗(yàn)試劑、微生物檢驗(yàn)試劑、分子生物學(xué)檢驗(yàn)試劑、臨床生化試劑、有機(jī)試劑等眾多領(lǐng)域，同時(shí)核心代理Panbio、FOCUS、Qiagen、IBL、CORTEZ、Fuller、Inbios、BinaxNOW、LumuQuick、日本富士、日本生研等多家有名診斷產(chǎn)品集團(tuán)公司產(chǎn)品，致力于為商檢單位、疾病預(yù)防控制中心、海關(guān)出入境檢疫局、衛(wèi)生防疫單位,緝毒系統(tǒng)，戒毒中心，檢驗(yàn)檢疫單位、生化企業(yè)、科研院所、醫(yī)療機(jī)構(gòu)等機(jī)構(gòu)與行業(yè)提供*、高品質(zhì)的產(chǎn)品服務(wù)。此外，本公司還開展食品、衛(wèi)生、環(huán)境、藥品等多方面的第三方檢測服務(wù)。

廣州健侖生物長期供應(yīng)各種違禁品檢測試紙、違禁品檢測卡、違禁品檢測試劑盒、藥篩試紙、藥篩試劑盒、嗎啡檢測試劑盒、巴比妥檢測試劑盒等。

使用說明書

【產(chǎn)品名稱】

通用名稱：違禁品膠體金單克隆抗原

英文名稱：Diagnostic Kit for Nicotine（Colloidal Gold）

【包裝規(guī)格】 

1人份/袋、40人份/盒

Multi DOA Screen Panel are rapid chromatographic immunoassays for the qualitative and simultaneous detection of one to fourteen of the following drugs in a variety of combinations in human urine. The designed cutoff concentrations and direct calibrator for these drugs are as follows:

The test is used to obtain visual qualitative result and is intended for health care professionals use including professionals at point of care sites to assist in the determination of drug compliance. It is not intended for over the counter sale to non-professionals.

This assay provided only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/ Mass Spectrometry (GC/MS) or Liquid Chromatography/ Mass Spectrometry (LC/MS) are the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

本品采用競爭抑制法和膠體金免疫層析技術(shù)，用于定性檢測人體尿液中尼古丁，適用于尼古丁藥物濫用的初步篩查。

主營品牌：美國NovaBios、美國Cortez、國產(chǎn)創(chuàng)侖等等。

主要用途：篩查違禁品濫用殘留、麻醉藥殘留、興奮藥物殘留等等。

檢測范圍：嗎啡、KET、mamp、MDMA、BZO、THC、巴比妥、MTD、BAR、MDMA、AMP、BUP、PCP、TCA、OXY、MET等等。

產(chǎn)品特點(diǎn)：可以根據(jù)需求自主訂制多聯(lián)卡。多聯(lián)卡自由組合，從二聯(lián)到十五聯(lián)都可以訂制。

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

如需訂購或者了解請以下或

mob： 楊   ： 

美國NOVABIOS多聯(lián)檢測杯簡介：

美國NOVABIOS單卡產(chǎn)品簡介：

w the test device, urine specimen, and/or controls to reach room temperature (15-30oC) prior to t

更多產(chǎn)品說明可通過下方的進(jìn)行了解

添加掃一掃二維碼：

【公司名稱】 廣州健侖生物科技有限公司

【 市場部 】       楊永漢
【】 
【騰訊  】
【公司地址】 廣州市清華科技園健新基地番禺石樓鎮(zhèn)健啟路63號(hào)二期2幢101-103室

人類進(jìn)化遺傳學(xué)中運(yùn)用  分子鐘技術(shù)推算出了線粒體 夏娃zui晚出現(xiàn)的時(shí)間（這個(gè)成果被認(rèn)  為是人類由非洲單地起源的 有力依據(jù)）是利用mtDNA研究群體遺傳  學(xué)的典型例子。另外一個(gè) 例子是對(duì)尼安德特人骨骼化石中mtDNA測  序。該測序的結(jié)果顯示 ，尼安德特人與解剖學(xué)意義上的現(xiàn)代人在  mtDNA序列上有較大差 異，說明兩者間缺乏基因交流。雖然mtDNA  在遺傳學(xué)研究中占據(jù) 了重要地位，但是mtDNA序列中的信息只能反  映所考察的群體中 的雌性成員的演化進(jìn)程，而不能代表整個(gè)種群  。這一缺陷需要由 對(duì)父系遺傳序列（如Y染體上的非重組區(qū)）的測  序彌補(bǔ)。廣義上 來說，只有既考慮了mtDNA又考慮了核DNA的遺傳  學(xué)研究才能為 種群的進(jìn)化史提供全面的線索。病理編輯線粒體是  對(duì)各種損傷zui 為敏感的細(xì)胞器之一。在細(xì)胞損傷時(shí)zui常見的病理  改變可概括為 線粒體數(shù)量、大小和結(jié)構(gòu)的改變：數(shù)量的改變線粒  體的平均壽命 約為天。衰亡的線粒體可通過保留的線粒體直接分  裂為二予以補(bǔ) 充。在病理狀態(tài)下，線粒體的增生實(shí)際上是對(duì)慢性  非特異性細(xì)胞 損傷的適應(yīng)性反應(yīng)或細(xì)胞功能升高的表現(xiàn)。
The use of molecular clock technology in the evolutionary genetics of humans deduced that the most recent occurrence of mitochondria Eve (this result is considered to be a strong basis for the single origin of humans from Africa) is a typical example of the use of mtDNA to study population genetics. Another example is the mtDNA sequencing of Neanderthal bone fossils. The results of this sequencing show that Neanderthals and modern humans in the anatomical sense are quite different in the mtDNA sequence, indicating that there is a lack of gene exchange between the two. Although mtDNA occupies an important position in genetic studies, the information in mtDNA sequences can only reflect the evolutionary process of the female members of the investigated population and does not represent the entire population. This deficiency needs to be compensated by the sequencing of paternal genetic sequences (such as non-recombination regions on Y-body). In a broad sense, only genetic studies that consider both mtDNA and nuclear DNA can provide comprehensive clues to the evolutionary history of the population. The pathological editing of mitochondria is one of the most sensitive organelles to various injuries. The most common pathological changes in cell damage can be summarized as changes in the number, size, and structure of mitochondria: changes in the number of mitochondria have an average life span of approximay days. Decaying mitochondria can be complemented by the splitting of the retained mitochondria to two. In pathological conditions, mitochondrial hyperplasia is actually an indication of an adaptive response to chronic nonspecific cell injury or an increase in cell function.